Arkolith/Insider Trading/TNYA/Form 4

Ali Faraz

Chief Executive Officer, DirectorTenaya Therapeutics, Inc. (TNYA) · full profile →Form 4 · filed Feb 7, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
9
2 non-derivative · 7 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 6, 2025Grant(A)108K—$0296K
Feb 6, 2025Grant(A)34K—$0330K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 6, 2025Disposed to issuer(D)353K——0
Feb 6, 2025Grant(A)401K——401K
Feb 6, 2025Disposed to issuer(D)401K——0
Feb 6, 2025Grant(A)161K——161K
Feb 6, 2025Disposed to issuer(D)161K——0
Feb 6, 2025Grant(A)650K—$0650K
Feb 6, 2025Grant(A)353K——353K

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-016582) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML